Citizens Financial Group Inc. RI increased its holdings in shares of Pfizer Inc. (NYSE:PFE – Free Report) by 63.5% in the 2nd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 200,310 shares of the biopharmaceutical company’s stock after buying an additional 77,780 shares during the quarter. Citizens Financial Group Inc. RI’s holdings in Pfizer were worth $5,605,000 at the end of the most recent reporting period.
Several other large investors have also bought and sold shares of PFE. Olistico Wealth LLC bought a new stake in shares of Pfizer during the second quarter worth $25,000. MFA Wealth Advisors LLC bought a new stake in Pfizer during the 2nd quarter worth $29,000. Creekmur Asset Management LLC acquired a new position in Pfizer in the 4th quarter worth about $32,000. Trivant Custom Portfolio Group LLC raised its position in Pfizer by 100.0% in the first quarter. Trivant Custom Portfolio Group LLC now owns 1,200 shares of the biopharmaceutical company’s stock valued at $33,000 after purchasing an additional 600 shares during the last quarter. Finally, Financial Connections Group Inc. acquired a new stake in shares of Pfizer during the second quarter valued at about $34,000. 68.36% of the stock is owned by institutional investors and hedge funds.
Pfizer Stock Performance
NYSE:PFE opened at $30.07 on Tuesday. The company has a quick ratio of 0.60, a current ratio of 0.86 and a debt-to-equity ratio of 0.65. Pfizer Inc. has a twelve month low of $25.20 and a twelve month high of $34.12. The company has a fifty day moving average of $29.26 and a 200-day moving average of $28.15. The firm has a market capitalization of $170.40 billion, a P/E ratio of -501.08, a P/E/G ratio of 1.02 and a beta of 0.68.
Pfizer Dividend Announcement
The company also recently disclosed a quarterly dividend, which was paid on Tuesday, September 3rd. Stockholders of record on Friday, July 26th were issued a dividend of $0.42 per share. The ex-dividend date was Friday, July 26th. This represents a $1.68 annualized dividend and a dividend yield of 5.59%. Pfizer’s dividend payout ratio is -2,799.53%.
Analyst Ratings Changes
PFE has been the subject of a number of research reports. UBS Group raised their price objective on shares of Pfizer from $30.00 to $31.00 and gave the company a “neutral” rating in a report on Wednesday, July 31st. Barclays lifted their price target on shares of Pfizer from $30.00 to $32.00 and gave the stock an “equal weight” rating in a report on Wednesday, July 31st. Cantor Fitzgerald restated an “overweight” rating and issued a $45.00 price objective on shares of Pfizer in a report on Monday. Daiwa America raised Pfizer from a “moderate buy” rating to a “strong-buy” rating in a report on Wednesday, August 7th. Finally, StockNews.com raised Pfizer from a “hold” rating to a “buy” rating in a research note on Thursday, August 1st. Eight equities research analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, Pfizer has a consensus rating of “Moderate Buy” and an average target price of $34.54.
Read Our Latest Stock Analysis on PFE
About Pfizer
Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.
Read More
- Five stocks we like better than Pfizer
- The How And Why of Investing in Oil Stocks
- Palo Alto Analysts Drive it to New Highs: 50% Upside Is Possible
- How to buy stock: A step-by-step guide for beginners
- Roblox’s Growth Beyond Kids: Stock Set for Major Moves
- Best Stocks Under $10.00
- 5 Oversold Stocks to Buy Right Now
Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.